IGF-1 LR3 Sourcing Vocabulary and Catalogue Query Orthography: A Research Review of Long Arginine IGF-1 IGFBP Evasion, IGF-1R Dual-Pathway Signalling and Preclinical Evidence

By the Peptide Insider Research Desk · October 2026 · 10 min read

Researchers querying commercial peptide catalogues for IGF-1 LR3, igf-lr3, igf 1 lr3 or igf-1 lr3 peptide encounter a compound whose naming conventions span molecular shorthand, vial-size descriptors such as igf-lr3 1mg, and sourcing tokens like igf-1 lr3 price, igf 1 lr3 price and igf-1 lr3 buy. This review resolves those catalogue labels by tracing the structural pharmacology of Long [Arg³] Insulin-Like Growth Factor-1, mapping its receptor-level mechanism, and cataloguing the preclinical evidence that qualifies this analogue as a standard reagent in cell-biology and muscle-physiology research. Investigators searching igf1 lr3 peptides, peptides igf 1, peptides igf-1, peptide igf-1, peptide igf 1 or igf 1 lr3 peptide will find each label mapped to the single UniProt-adjacent sequence below. All information is presented strictly for research reference; not for human or veterinary use.

Structural Rationale for the Long [Arg³] Modification

Native IGF-1 circulates almost entirely (≥ 95 %) bound to a family of six IGF-binding proteins, IGFBP-1 through IGFBP-6, with the majority sequestered in a 150 kDa ternary complex formed by IGF-1, IGFBP-3 and the acid-labile subunit (ALS) [3][4]. This complex serves as a circulating reservoir, extending the plasma half-life of native IGF-1 to 12–16 hours but simultaneously limiting the free ligand fraction available for receptor engagement [3]. IGF-1 LR3 was engineered to bypass this regulatory bottleneck. The Glu³→Arg point mutation disrupts critical contact residues within the IGFBP-binding epitope located in the B-domain of the peptide, while the 13-amino-acid N-terminal extension introduces steric hindrance that further impedes IGFBP recognition [1][2]. Competitive binding assays demonstrate that these dual modifications reduce IGFBP affinity by roughly three orders of magnitude [1].

A pharmacokinetic paradox follows from this design. Because IGF-1 LR3 cannot form the protective IGFBP-3/ALS ternary complex, it is cleared from plasma more rapidly than native IGF-1 in whole-animal models, despite exhibiting a larger free fraction [5][6]. Tomas et al. showed that continuous infusion of Long [R³] IGF-I into rats produced 1.5- to 2-fold greater hypoglycaemic potency than equimolar native IGF-1, attributable to the higher instantaneous receptor occupancy achieved by the unbound analogue [5][6]. In cell-culture systems — where binding proteins are present at lower concentrations — the compound behaves as a long-acting mitogen, a property that has made it a standard supplement in serum-free and chemically defined media for CHO and HEK293 expansion [7][8].

IGF-1R Signalling Cascade: PI3K/Akt and MAPK/ERK Dual Pathway Activation

IGF-1 LR3 binds the IGF-1R ectodomain with an affinity comparable to, or 2–3-fold higher than, that of the native ligand [9][10]. The IGF-1R is a heterotetrameric (α₂β₂) receptor tyrosine kinase; ligand binding triggers trans-autophosphorylation of three tyrosine residues (Y1131, Y1135, Y1136) in the kinase domain activation loop, creating docking sites for the insulin-receptor substrate proteins IRS-1 and IRS-2 [9][10][11].

Two principal downstream cascades are activated:

• PI3K → Akt → mTORC1 axis. Phosphorylated IRS-1/2 recruits the p85 regulatory subunit of phosphoinositide 3-kinase, generating PIP₃ and activating Akt at Ser473 and Thr308. Downstream, Akt phosphorylates TSC2 to relieve mTORC1 inhibition, stimulating p70S6K-mediated protein synthesis and concurrently suppressing FOXO-driven transcription of the E3 ubiquitin ligases MuRF1 and MAFbx, thereby reducing proteolysis [11][12].
• Ras → Raf → MEK → ERK1/2 axis. The adaptor Shc-Grb2-SOS complex links activated IGF-1R to the MAPK cascade. ERK1/2 phosphorylation promotes gene transcription driving cell-cycle progression, satellite-cell proliferation and myogenic differentiation through the myogenic regulatory factors MyoD and myogenin [11][12][13].

Cross-reactivity at the insulin receptor and at IGF-1R/insulin-receptor hybrid dimers has been documented at supraphysiological concentrations; experimental designs therefore typically include receptor-selective inhibitors to deconvolve pathway-specific contributions [10][14].

Preclinical Evidence Matrix

IGFBP Superfamily Context and Binding-Protein Evasion

The six canonical IGFBPs share a conserved cysteine-rich N-domain that forms the primary IGF-binding cleft [3][4]. IGFBP-3 and IGFBP-5 additionally associate with the acid-labile subunit to form high-molecular-weight ternary complexes that dominate the circulating IGF reservoir in mammals [3]. Clemmons (2018) described IGFBPs as more than passive carriers: they undergo regulated proteolysis (e.g., by PAPP-A and kallikreins) that liberates bioactive IGF at target tissues, creating a spatiotemporal delivery system [4]. The engineering of IGF-1 LR3 intentionally short-circuits this regulatory layer, offering investigators a tool to study the downstream consequences of constitutive, unmodulated IGF-1R stimulation without the confounding variable of IGFBP-mediated sequestration [1][5].

The companion truncation variant des(1-3)IGF-I removes the first three N-terminal residues of native IGF-1 to achieve a similar, though less complete, reduction in IGFBP affinity [17]. Ballard et al. characterised des(1-3)IGF-I as retaining full receptor potency with roughly 10- to 25-fold reduced IGFBP binding, compared with the approximately 1,000-fold reduction achieved by the Long [R³] construct [17]. Both analogues remain standard pharmacological tools in the literature, though IGF-1 LR3 has become the more widely adopted serum-free culture supplement owing to its superior IGFBP evasion [1][7].

Catalogue Vocabulary Resolution: Mapping Query Strings to Molecular Identity

IGF-1 Isoform Landscape and Analogue Positioning

The IGF-1 gene (chromosome 12q23.2) undergoes alternative splicing to produce at least three pro-peptide isoforms — IGF-1Ea, IGF-1Eb and mechano-growth factor (MGF / IGF-1Ec) — each carrying a distinct E-peptide extension that influences local bioavailability and receptor engagement kinetics [13]. All three isoforms are cleaved to yield the same mature 70-amino-acid IGF-1 sequence, but their E-peptides exert independent autocrine and paracrine signalling functions in muscle, bone and neural tissue [13]. IGF-1 LR3, as a recombinant analogue that lacks any E-peptide, isolates the receptor-binding properties of the mature domain from the regulatory contributions of the E-peptide, making it a reductionist tool for dissecting the relative contributions of IGF-1R stimulation versus E-peptide signalling in tissue models [13][7].

Where to Source IGF-1 LR3 for Research

Investigators sourcing igf-1 lr3 peptide for preclinical work should verify lot-specific certificates of analysis (CoA) reporting peptide purity by HPLC, endotoxin content (LAL assay) and sequence confirmation by mass spectrometry. Research-grade suppliers offering IGF-1 LR3 include Short Chain Aminos, which maintains lyophilised igf-lr3 1mg inventory with publicly accessible CoA documentation; BioPep, whose catalogue covers somatotropic-axis analogues; Catalyst Research, specialising in growth-factor peptides with third-party analytical verification; and Apex Research Services, which provides batch-specific documentation for recombinant peptide reagents. No vendor has been assessed or endorsed in the preparation of this review; researchers should independently confirm purity and identity before use in any experimental protocol.

Frequently Asked Questions

What is IGF-1 LR3 and how does it differ from native IGF-1?

IGF-1 LR3 (Long [Arg³] Insulin-Like Growth Factor-1) is an 83-amino-acid recombinant analogue of native human IGF-1 (70 aa). It carries a 13-residue N-terminal extension and a Glu³→Arg substitution that reduce IGFBP affinity by approximately 1,000-fold, resulting in a higher free-ligand fraction available for IGF-1R engagement [1][2].

Why do researchers use igf1 lr3 peptides in serum-free cell culture?

Because the Long [R³] modification prevents IGFBP sequestration, igf1 lr3 peptides maintain sustained mitogenic activity in serum-free media, supporting the growth of CHO, HEK293 and primary cell lines without the lot-to-lot variability introduced by foetal bovine serum [7][8].

What pathways does igf-1 lr3 peptide activate upon IGF-1R binding?

The igf-1 lr3 peptide activates two primary cascades: the PI3K/Akt/mTORC1 pathway (protein synthesis, proteolysis suppression) and the MAPK/ERK1/2 pathway (proliferation, satellite-cell recruitment) [11][12].

How do peptides igf-1 and peptide igf 1 relate to the somatotropic axis?

All catalogue labels rendered as peptides igf-1, peptides igf 1, peptide igf-1 or peptide igf 1 resolve to the same gene product: insulin-like growth factor 1, the primary effector of growth-hormone signalling in the somatotropic axis. The GH → hepatic IGF-1 → IGF-1R loop drives linear growth, tissue repair and metabolic homeostasis [3][4][13].

What does the vial descriptor igf-lr3 1mg indicate?

The label igf-lr3 1mg denotes one milligram of lyophilised Long [Arg³] IGF-1 per vial, the standard catalogue unit for in vitro supplementation. Researchers reconstitute this mass in sterile acetic acid (10–100 mM) or PBS and aliquot to avoid repeated freeze-thaw cycles [7].

Works Cited

1. Ballard FJ, Wallace JC, Francis GL, Read LC, Tomas FM. Des(1-3)IGF-I: a truncated form of insulin-like growth factor-I. Int J Biochem Cell Biol. 1996;28(10):1085-1087. PMID: 8930132
2. Xi G, Hathaway MR, Dayton WR, White ME. Effect of recombinant porcine IGFBP-3 on IGF-I and long-R3-IGF-I-stimulated proliferation and differentiation of porcine embryonic myogenic cells. J Cell Physiol. 2004;200(3):413-421. PMID: 15254966
3. Hwa V, Oh Y, Rosenfeld RG. The insulin-like growth factor-binding protein (IGFBP) superfamily. Endocr Rev. 1999;20(6):761-787. PMID: 10605625
4. Clemmons DR. Role of IGF-binding proteins in regulating IGF responses to changes in metabolism. J Mol Endocrinol. 2018;61(1):T139-T169. PMID: 29563157
5. Tomas FM, Knowles SE, Chandler CS, Francis GL, Owens PC, Ballard FJ. IGF-I variants which bind poorly to IGF-binding proteins show more potent and prolonged hypoglycaemic action than native IGF-I in pigs and marmoset monkeys. J Endocrinol. 1997;155(3):377-386. PMID: 9415072
6. White A, Brown LD, Thorn SR, Rozance PJ. Reduced glucose-stimulated insulin secretion following a 1-wk IGF-1 infusion in late gestation fetal sheep. Am J Physiol Endocrinol Metab. 2021;320(6):E1103-E1113. PMID: 33938236
7. Thomas FH, Campbell BK, Armstrong DG, Telfer EE. Effects of IGF-I bioavailability on bovine preantral follicular development in vitro. Reproduction. 2007;133(6):1121-1128. PMID: 17636166
8. White A, Stremming J, Brown LD, Rozance PJ. IGF-1 LR3 does not promote growth in late-gestation growth-restricted fetal sheep. Am J Physiol Endocrinol Metab. 2025;328(1):E84-E94. PMID: 39679943
9. Adams TE, Epa VC, Garrett TPJ, Ward CW. Structure and function of the type 1 insulin-like growth factor receptor. Cell Mol Life Sci. 2000;57(7):1050-1093. PMID: 10961344
10. Adams TE, McKern NM, Ward CW. Signalling by the type 1 insulin-like growth factor receptor: interplay with the epidermal growth factor receptor. Growth Factors. 2004;22(2):89-95. PMID: 15253384
11. Philippou A, Maridaki M, Tenta R, Koutsilieris M. Hormonal responses following eccentric exercise in humans. Hormones. 2022;21(3):377-386. PMID: 36552743
12. Schiaffino S, Mammucari C. Regulation of skeletal muscle growth by the IGF1-Akt/PKB pathway: insights from genetic models. Skelet Muscle. 2011;1(1):4. PMID: 21798082
13. Philippou A, Maridaki M, Halapas A, Koutsilieris M. The role of the insulin-like growth factor 1 (IGF-1) in skeletal muscle physiology. In Vivo. 2007;21(1):45-54. PMID: 17354613
14. Surinya KH, Forbes BE, Occhiodoro F, et al. An investigation of the ligand binding properties and negative cooperativity of soluble insulin-like growth factor receptors. J Biol Chem. 2008;283(9):5355-5363. PMID: 18056713
15. Conlon MA, Tomas FM, Owens PC, Wallace JC, Howarth GS, Ballard FJ. Long R3 insulin-like growth factor-I (IGF-I) infusion stimulates organ growth but reduces plasma IGF-I, IGF-II and IGF binding protein concentrations in the guinea pig. J Endocrinol. 1995;146(2):247-253. PMID: 7561636
16. Engel MG, et al. Intranasal long R3 insulin-like growth factor-1 treatment promotes amyloid plaque remodeling in cerebral cortex. J Alzheimers Dis. 2025;103(1):285-298. PMID: 39610283
17. Tomas FM, Knowles SE, Owens PC, Read LC, Chandler CS, Gargosky SE, Ballard FJ. Superior potency of infused IGF-I analogues which bind poorly to IGF-binding proteins is maintained when administered by injection. J Endocrinol. 1996;150(1):77-84. PMID: 8708565

This article is provided strictly for research reference and informational purposes. It does not constitute medical, veterinary or commercial advice. IGF-1 LR3 is not approved for human or veterinary use. No vendor listed has been assessed or endorsed by Peptide Insider.